Epic Sciences announced that Lloyd Sanders has joined the company as president and chief executive officer.
Sanders comes to Epic from Myriad Genetics where he served as president of the company’s oncology segment. While at Myriad, Sanders oversaw commercial operations and sales and marketing in oncology, urology and dermatology product areas.
“Epic has established an impressive position in the prostate cancer liquid biopsy market and I am eager to work with the team to advance the mission of providing very powerful predictive, actionable information to physicians and patients that can extend lives,” said Sanders in a press release announcing his appointment. “By expanding the breadth and depth of Epic’s portfolio of reimbursed products, and building our thriving biopharma solutions business that supports our pharmaceutical partners’ development of next-generation immunotherapies and targeted cancer agents, we can play an important role in changing cancer from a lethal to a chronic, manageable disease.”
Sanders replaces Murali Prahalad, Ph.D., who stepped down after six years at the helm to pursue new opportunities. Prahalad has been appointed to Epic’s board of directors.
“Under Murali’s leadership, the Epic team has made substantial progress in advancing our proprietary Functional Cell Profiling platform and successfully launching and obtaining Medicare coverage for the world’s first predictive test for metastatic prostate cancer,” said Gregory T. Lucier, chairman of Epic Sciences. “As Murali continues to advise the company in his role as a director, we welcome Lloyd to the team to capitalize on our solid foundation. The trajectory has been set for significant commercial growth through Epic’s portfolio of high-value liquid biopsy tests and expansion into breast cancer, immuno-oncology and global markets. Lloyd and the leadership team, board, investors and Epic employees are highly motivated to take Epic to the next level.”
